Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan

BMC Gastroenterology

Table 3 Risk factors for positive seroconversion of HBsAg in HBsAg-negative patients detected during diagnosis of hematological malignancy

	Positive Sero- conversion (n = 41)	No conversion (n = 1635)	Univariate P value	Multivariate P value	Odds ratio (95% CI)
Age			0.174	NA
≧65 years	12	466
< 65 years	29	1169
Gender			0.737	NA
Men	22	866
Women	19	769
Hematological malignancy			0.038	0.084	NA
AML	5	526
ALL	7	140
Lymphoma	24	603
CML/MPN	0	54
CLL	1	21
Myeloma	3	163
MDS / AA	1	128
Diabetes mellitus			0.040	0.005	0.218(0.076–0.629)
Yes	10	233
No	31	1402
Allogeneic transplantation			0.116	0.013	0.182(0.047–0.701)
Yes	15	365
No	26	1270
Liver cirrhosis			<0.001	<0.001	0.002(0.000–0.047)
Yes	2	8
No	39	1627
Hepatocellular carcinoma			0.748	NA
Yes	0	5
No	41	1630
Hepatitis C			0.216	NA
Yes	0	65
No	41	1570
Negative Anti-HBs Antibody^a			0.237	NA
Yes	10	304
No	24	1157
Low Anti-HBs Antibody ^a			0.002	0.016	0.020(0.001–0.480)
Yes	30	915
No	4	546
Positive Anti-HBc Antibody^b			0.005	0.013	0.070(0.009–0.571)
Yes	18	567
No	1	263

NA not available, ^a Anti-HBs Antibody checked, (n = 1495), Low Anti-HBs Antibody <100mIU/mL, ^b Anti-HBc Antibody checked (n = 849), AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML/MPN chronic myeloid leukemia/myeloproliferative neoplasm, CLL chronic lymphocytic leukemia, MM myeloma, MDS/AA myelodysplastic syndrome/aplastic anemia

ISSN: 1471-230X